The global Peptide Drug Conjugates market size was estimated to be US$ 575 million in 2021 and is expected to grow at a CAGR of 16% between 2023 to 2032.
The primary components of life, peptides, and proteins are one of the most effective therapies for treating a wide range of disorders. Over the past ten years, there has been a sharp increase in the development of therapeutic proteins due to the rising need for protein-based medications. Many of the peptides being tested in the clinical study are used to treat a variety of conditions, including cancer, cardiovascular illness, respiratory disorders, metabolic disorders, central nervous system diseases, etc.
Peptide therapies have several benefits, including enhanced potency and selectivity, which are expected to increase demand in the years to come. Growing investments in the drug development space by several major firms to bring new peptide medications to market and the rising incidence of metabolic illnesses & cancer are estimated to propel the market expansion for peptide therapeutics over the anticipated period.
Additionally, increasing product releases by numerous important players through strategic alliances and acquisitions are predicted to drive market growth for peptide therapies throughout the course of the forecast year. The discovery of various novel methods for using peptides as therapeutic molecules, including peptide vaccines, peptide drug conjugates, anti-cancer peptides, fusion proteins, and others, is the result of technological developments in the field of biotechnology.
During the forecast period, it is anticipated that the use of Peptide-Drug Conjugates (PDCs) therapy for patients with various cancers will lead to a number of clinical possibilities. A homing peptide, a linker, and a cytotoxic payload that targets the tumor cell and releases the cytotoxin are all essential parts of peptide drug conjugates.
PDC has a peptide chain of approximately ten amino acids that target tumor cells. Its molecular weight is lower than that of antibody-drug conjugates (ADCs), which can be rapidly enriched to tumor sites. Drug molecules in the blood can also be cleared quickly and have a short half-life, which helps to reduce toxic side effects brought on by off-targeting.
Over the forecast period, rising rates of metabolic diseases and cardiovascular disorders (CVDs) are anticipated to fuel market expansion for peptide therapies. Additionally, rising healthcare costs are anticipated to support market expansion. The worldwide generic peptide therapeutics market will have much potential to grow at a large rate in the predicted period as a result of the patent expiration of various peptide medications in the next few years.
The market for peptide drug conjugates can be divided into subgroups according to marketing type, administration route, application, and other factors. The peptide drug conjugates market can be divided into generic peptides and branded peptides based on the type of marketing used.
The peptide drug conjugates market may be divided into the oral mode of administration and the parenteral mode of administration based on the route of administration. The market for peptide drug conjugates was dominated by the Lutathera product group.
It is approved for the treatment of people with gastroenteropancreatic neuroendocrine tumors that express the somatostatin receptor, including those of the foregut, midgut, and hindgut. The radiotherapeutic substance 177Lu and the homing peptide somatostatin are linked by an amide in Lutheran. Due to the enormous advantages of PDCs in the therapeutic segment, pharmaceutical companies are also developing therapeutic PDCs with a focus on metabolic illnesses and coronavirus diseases in addition to cancer.
Additionally, the market can be divided into subgroups depending on applications, such as cancer, acromegaly, cardiovascular diseases, infections, respiratory disorders, central nervous system disorders, metabolic disorders, and others. Due to the rising number of new cases of cancer, cancer dominates the market.
The market for peptide drug conjugates has been divided geographically into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Due to its large concentration of pharmaceutical companies, increased research activity in the field of proteomics and genomics and increasing investments by major market participants in the creation of novel peptide drug molecules, North America is predicted to dominate the global market for peptide therapeutics.
The expansion of the peptide drug conjugates market in Europe is anticipated to be aided by rising awareness of the applications of peptides for the treatment of various chronic disorders. Due to the rising patient population and the existence of numerous important companies in the life science research industry, the Asia Pacific peptide drug conjugates market is predicted to expand at a significant rate.
The expansion of the worldwide peptide drug conjugates market is anticipated to be constrained by naturally occurring peptides' poor chemical and physical stability and brief plasma half-life. Furthermore, the existence of strict safety rules is also limiting market expansion. Because peptide therapies treat a variety of pathological disorders, a better regulatory framework is expected for pharmaceutical goods like these.
The key players involved in peptide–drug conjugates (PDCs) industry are Novartis AG, AstraZeneca, Bicycle Therapeutics, Cybrexa Therapeutics, Esperance Pharmaceuticals, Oncopeptides AB, Pepgen Corporation, Soricimed, Biopharma, Theratechnologies, Pfizer Inc, Validus Pharmaceuticals LLC, Antisense Therapeutics, Midatech Pharma PLC, Ipsen Pharma, Chiasma, Inc., Peptron, Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Camurus, AB, Teva Pharmaceuticals Inc., etc
The peptide drug conjugates market is expected to increase at a CAGR of 16% from 2023 to 2032.
The worldwide peptide therapies market is expected to be restrained by naturally occurring peptides' poor chemical and physical stability and short plasma half-life.
Based on product, the Lutathera segment had the largest market share because it is the first PDC to receive approval and it addresses a need in neuroendocrine tumours.
The global increase in cancer cases and accompanying mortality, the strong clinical pipeline of PDCs, and the uncontrolled toxicity associated with the existing small molecule chemotherapeutic treatments are the main reasons driving the market expansion.
The peptide drug conjugates market size was estimated to be US$ 575 million in 2021.
Copyright © 2023 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved